David Payne, a 40-year veteran of the medical device and pharmaceutical industries, is the new Vice President of Business Development at Fall River, Massachusetts-based Millstone Medical Outsourcing.
David Payne New VP, Business Development at Millstone Medical

Payne comes to Millstone from DePuy Synthes where he was director of External Supply Integration for North America. He joined Johnson & Johnson in 1996 and proceeded to hold numerous positions of increasing responsibility within procurement, including Director, Metals and Instruments Category and Group Commodity Manager.
“We are delighted to welcome David to his new role with Millstone,” Commercial President Kelly Lucenti said. “David has developed tremendous strength and experience in the supply chain and sourcing side of the medical device business. His experience with pharmaceutical is a valuable addition and together with his med device expertise makes him an ideal fit for this new role on our team. We are confident that David will help us continue Millstone’s growth as a company.”
Payne, who earned a bachelor’s degree from Northeastern University, began his career at Pfizer Hospital Products, where he held positions in distribution, customer solutions, and procurement.
“I am so energized about this latest chapter in my career,” David Payne said. “This new role builds on the experience I have gained on the procurement side of the business over the last 20 years. I am thrilled to have the opportunity to help drive Millstone’s growth while continuing to work with colleagues and contacts from my business network. In this role I am able to help many of my former co-workers solve problems by tapping into Millstone as a new resource.”
“My focus is to reconnect with my network within Johnson & Johnson to identify products and projects where Millstone can help bring value and solutions to enhance their supply chain,” Payne told OTW.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.